Status:
COMPLETED
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
Lead Sponsor:
Taisho Pharmaceutical Co., Ltd.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
Eligibility Criteria
Inclusion
- Males or females of non-childbearing capacity aged 18 to 55 years inclusive
- DSM-IV diagnosis of schizophrenia, stable symptoms for at least 3 months
- Body mass index in the range of 18 to 40 kg/m2 and body weight\>45 kg.
Exclusion
- Evidence or history of a primary DSM IV axis I diagnosis other than schizophrenia.
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
- Any condition possibly affecting drug absorption (eg, gastrectomy).
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00876304
Start Date
April 1 2009
End Date
September 1 2009
Last Update
March 19 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Glendale, California, United States, 91206